Association Between the Tissue and Circulating Advanced Glycation End-Products and the Micro- and Macrovascular Complications in Type 1 Diabetes: The DIABAGE Study

• Published in: Diabetes therapy 2022-08, Vol.13 (8), p.1531-1546
• Main Authors: Diallo, Alpha M., Jaisson, Stéphane, Barriquand, Romain, Lukas, Céline, Barraud, Sara, Decoudier, Bénédicte, Francois, Maud, Ly, Sang, Mahmoudi, Rachid, Arndt, Carl, Nazeyrollas, Pierre, Gillery, Philippe, Delemer, Brigitte
• Format: Article
• Language: English
• Subjects: Cardiology; Diabetes; Diabetic neuropathy; Endocrinology; Human health and pathology; Internal Medicine; Life Sciences; Medicine; Medicine & Public Health; Original Research; Vein & artery diseases; Veins & arteries
• ISSN: 1869-6953; 1869-6961
• DOI: 10.1007/s13300-022-01285-1

Introduction Type 1 diabetes is associated with an increased risk of vascular complications. We aimed to investigate the association between serum and tissue advanced glycation end-products (AGEs) and micro- and macrovascular complications in type 1 diabetes (T1D). Methods We conducted a cross-sectional study on 196 adults with T1D (mean age 44.53 ± 16, mean duration of diabetes 22 ± 12 years, mean HbA1c 8 ± 1.2%). AGEs were measured in blood serum (i.e., carboxymethyllysine (CML), methylglyoxal-hydroimidazolone-1 (MGH1), and pentosidine) and by measurement of skin autofluorescence (SAF). Associations between AGEs levels and vascular complications were analyzed using binary logistic regression. Correlations between AGEs and pulse wave velocity (PWV) were also assessed by linear regressions. Significant differences were set for p values less than 0.05. Results We found positive associations between different AGEs and vascular complications. SAF was associated with both microangiopathy (retinopathy: OR = 1.92, p  = 0.011; neuropathy: OR = 2.02, p  = 0.04; any microangiopathy: OR = 2.83, p